The estimated Net Worth of Arpa Garay is at least $338 mil dollars as of 5 December 2023. Arpa Garay owns over 1,141 units of Moderna Inc stock worth over $338,236 and over the last 3 years Arpa sold MRNA stock worth over $0.
Arpa has made over 7 trades of the Moderna Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Arpa exercised 1,141 units of MRNA stock worth $90,721 on 5 December 2023.
The largest trade Arpa's ever made was exercising 4,562 units of Moderna Inc stock on 5 June 2023 worth over $362,725. On average, Arpa trades about 1,270 units every 73 days since 2022. As of 5 December 2023 Arpa still owns at least 4,254 units of Moderna Inc stock.
You can see the complete history of Arpa Garay stock trades at the bottom of the page.
Arpa's mailing address filed with the SEC is C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139.
Over the last 6 years, insiders at Moderna Inc have traded over $2,713,086,305 worth of Moderna Inc stock and bought 52,631 units worth $999,989 . The most active insiders traders include Noubar Afeyan, David M. Rubenstein, eStephane Bancel. On average, Moderna Inc executives and independent directors trade stock every 2 days with the average trade being worth of $2,841,687. The most recent stock trade was executed by Shannon Thyme Klinger on 6 September 2024, trading 1,139 units of MRNA stock currently worth $90,562.
moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a
Moderna Inc executives and other stock owners filed with the SEC include: